Novel 5-fluorouracil derivatives of the general formula: ##STR1## wherein R1, R2 and R3 each represent hydrogen atom or methyl group, and R4 represents a straight or branched alkyl or alkenyl group, which has low toxicity and improved antitumor activity, and novel antitumor preparations containing the said 5-fluorouracil derivative.
|
1. A 5-fluorouracil derivative represented by the general formula: ##STR41## wherein R1, R2 and R3 each represent hydrogen or methyl, and R4 represents a straight or branched chain alkyl or alkenyl group.
10. An antitumor agent containing an effective anti-tumor amount of a 5-fluorouracil derivative represented by the general formula ##STR42## wherein R1, R2 and R3 each represent hydrogen or methyl, and R4 represents a straight or branched chain alkyl or alkenyl group having 1-16 carbons and a pharmaceutically acceptable carrier therefor.
2. The 5-fluorouracil derivative according to
3. The 5-fluorouracil derivative according to
4. The 5-fluorouracil derivative according to
5. The 5-fluorouracil derivative according to
6. The 5-fluorouracil derivative according to
7. The 5-fluorouracil derivative according to
8. The 5-fluorouracil derivative according to
9. The 5-fluorouracil derivative according to
|
|||||||||||||||||||||||||||||||||||
This invention relates to a novel 5-fluorouracil derivative having the general formula (I) ##STR2## wherein R1, R2 and R3 each represent hydrogen atom or methyl group, and R4 represents a straight or branched alkyl or alkenyl group. This invention also relates to antitumor preparations containing said novel derivative.
Heretofore, there were used alkylating agents such as busulfan, chlorambutyl, merphalan and the like; and antimetabolics such as methotrexate, 6-mercaptopurine, 6-mercaptopurine ribo-nucleoside, 5-fluorouracil, and the like, for chemotherapeutics to various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer and the like. Among these chemotherapeutics, 5-fluorouracil has clinical utility. It is advantageous in that it is effective on many kinds of tumors; its effect is increased by combination therapies with other antitumor drug(s); and the effect of radiotherapy is enhanced by using 5-fluorouracil. However, close attention is required, because 5-fluorouracil shows relatively severe toxicity at the effective dosage. Under the circumstances, many investigations were made to find more useful 5-fluorouracil derivatives which were less toxic to the host and showed more activity to tumors. As a result of said investigation, N1 -(2'-tetrahydrofurfuryl)-5-fluorouracil (FT-207) was found.
FT-207 shows remarkably lower toxicity, i.e., 1/7-1/5 of that of 5-fluorouracil per se and less antitumor activity. However, in clinical application, a considerably long period of time is required to obtain remission by administration of FT-207 alone. We found novel 5-fluorouracil derivatives which show less toxicity than the known 5-fluorouracil, and also FT-207 and maintain high antitumor activity. And, we found that the desired object is attained by the derivatives (I) according to this invention.
An object of this invention is therefore to provide novel 5-fluorouracil derivatives having the general formula (I) as described above.
Another object of this invention is to provide a process for the preparation of 5-fluorouracil derivatives.
A further object of this invention is to provide novel antitumor preparations containing the 5-fluorouracil derivatives.
A still further object of this invention is to provide a method for treating various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer, and the like.
Other objects of this invention will be understood from the following descriptions.
There are various processes for the synthesis of said derivatives (I) depending on their chemical structures. One of the processes is explained as follows:
5-fluorouracil is reacted with a carbonate of 6-chromanol derivative having the general formula (II): ##STR3## wherein R1, R2, R3 and R4 have the same meanings as defined above, and X represents a halogen atom or a lower alkoxyl group, to obtain the desired derivatives (I). In this reaction, it is preferable to use the starting material, 5-fluorouracil, in a form of an alkali metal salt thereof. The reaction can advantageously progress by using an organic solvent such as dimethyl formamide, dimethyl acetamide, and the like. The reaction proceeds in an equimolar state and preferably at a temperature ranging from room temperature to about 50°C
The following shows the data of acute toxicities and antitumor activities of N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil according to this invention (hereinafter referred to the Compound A of this invention). FT-207 and 5-fluorouracil (hereinafter abbreviated to 5-FU) are selected as standard drugs.
LD50 (mg/Kg) after three weeks observation in CDF1 mice (female, 8-10 weeks old)
| Table 1 |
| ______________________________________ |
| Subcuta- |
| Intravenous |
| Intraperito- |
| neous Oral |
| administ- |
| neal administ- |
| administ- |
| admini- |
| ration ration ration stration |
| ______________________________________ |
| Compound A |
| -- >4000 >4000 >4000 |
| FT-207 750 800 830 930 |
| 5-FU 135 150 175 120 |
| ______________________________________ |
From Table 1, it is found that Compound A has a lower acute toxicity than FT-207 and 5-FU.
In addition, similar results were also obtained for the acute toxocity (LD50) in ICR/JCL mice.
(1) Inhibitory effect on the growth of S-180 ascites form (Intraperitoneal administration)
Implantation
106 cells of S-180 were intraperitoneally implanted in ICR/JCL mice (female, 8-10 weeks old).
Administration
To test groups:
Compound A was administered as a solution of soybean oil and 5-FU was administered as saline solution, at 24 hours after the implantation.
To control groups:
Soybean oil was administered as control for the Compound A. Saline solution was administered as control for 5-FU.
Observation
Ten days after the implantation of the tumor cells, the total packed cell volumes (TPCV) were measured. The measurement of TPCV was carried out in accordance with Hoshi, A. et al., Chemical & Pharmaceutical Bulletion 17 (4), 848-850 (1969). The results are shown in Table 2, wherein T/C % means the ratio of the TPCV of the test groups to that of the control group.
| Table 2 |
| ______________________________________ |
| Drugs Dose Number of Tumor growth |
| administered |
| (mg/Kg) animals (TPCV : T/C %) |
| ______________________________________ |
| Soybean oil |
| -- 16 100 |
| (control) |
| 4000 8 0 |
| Compound A |
| 2000 8 0 |
| 1000 8 0 |
| 500 8 3.3 |
| 250 8 30.4 |
| 125 8 64.7 |
| 62 8 77.5 |
| Saline |
| solution -- 16 100 |
| (control) |
| 500 8 (died) |
| 5-FU 250 8 (died) |
| 125 8 4.3 |
| 68 8 26.4 |
| 34 8 43.3 |
| ______________________________________ |
It is understood from Tables 1 and 2 that ED50 of the Compound A of this invention is about 170 mg/Kg and its safety index (LD50 /ED50) is more than 24, while ED50 of 5-FU is about 25 mg/Kg and its safety index is about 5. These results show that Compound A is less toxic as an antitumor agent.
(2) Survival effect
Implantation
106 cells of S-180 were intraperitoneally implanted in ICR/JCL mouse (female, 6-8 weeks old).
Administration
To test group:
Compound A was administered as a solution of soybean oil at 24 hours after the implantation.
To control group:
Soybean oil was administered as control for Compound A.
Observation
Survival days after implantation was measured. The increase in life-span over control groups (ILS = T/C % - 100) was calculated. The results are shown in Table 3.
| Table 3 |
| ______________________________________ |
| Mean ILS (%) |
| Drugs Dose Number of survival |
| over |
| administered |
| (mg/Kg) animals days control |
| ______________________________________ |
| Soybean oil |
| (Control) |
| -- 8 13.8 0 |
| 4000 8 39.0 182.6 |
| Compound A |
| 2000 8 36.0 160.9 |
| 1000 8 43.5 215.2 |
| 500 8 33.0 139.1 |
| ______________________________________ |
It is confirmed from Table 3 that Compound A exhibits a marked effect by a single administration of 1/8 LD50.
(3) Effect on growth of solid tumor by oral administration
Implantation
1.8 × 106 cells of S-180 were implanted subcutaneously in ICR/JCL mice (female, 6-8 weeks old).
Administration
To test group:
Each of the drugs was orally administered as a solution of safflower oil 3 hours after the implantation.
To control group:
Safflower oil was administered as control for each of the drugs.
Observation
Twenty days after, the tumor weight was measured, and the ratio of the tumor weight to that of the control group (T/C %) was calculated. The results are shown in Table 4.
| Table 4 |
| ______________________________________ |
| Drugs Dose Number of Tumor growth |
| administered |
| (mg/Kg) animals (weight : T/C %) |
| ______________________________________ |
| Safflower oil |
| -- 8 100 |
| (control) |
| 62 8 106 |
| 125 8 87 |
| Compound A |
| 250 8 33 |
| 500 8 47 |
| 1000 8 38 |
| 2000 8 36 |
| 25 8 148 |
| 50 8 269 |
| FT-207 100 8 58 |
| 200 8 43 |
| 400 8 34 |
| 10 8 156 |
| 5-FU 20 8 55 |
| 40 8 52 |
| 80 8 63 |
| ______________________________________ |
From Table 4, the minimum effective dose of Compound A is about 250 mg/Kg, that of FT-207 is about 100 mg/Kg, and that of 5-FU is about 20 mg/Kg. As for the ratios of the minimum effective dose to toxic dose (LD50) in each of the drugs, Compound A gives less than 1/16; FT-207 gives about 1/10; and 5-FU gives about 1/6. Therefore, the availability of the Compound A is higher than those of the other two drugs.
(1) Survival effect
Implantation
105 cells of L-1210 leukemia were intraperitoneally implanted in CDF1 mice (female, 8-10 weeks old).
Administration
To test group:
Compound A was intraperitoneally administered as a solution of medium chain triglyceride (MCT) at 24 hours after the implantation.
Each of 5-FU and FT-207 was also intraperitoneally administered as a saline solution at 24 hours after the implantation.
To control group:
MCT was administered as control for Compound A.
Saline solution was administered as controls for 5-FU and FT-207.
Observation
Mean survival time after the implantation was determined, and the increase in life-span (ILS) over controls was calculated. The results are shown in Table 5.
| Table 5 |
| ______________________________________ |
| Mean ILS % |
| Drugs Dose Number of survival |
| over |
| administered |
| (mg/Kg) animals days controls |
| ______________________________________ |
| MCT -- 6 7.0 0 |
| (control) |
| 125 6 7.0 0 |
| 250 6 8.0 14 |
| Compound A |
| 500 6 9.8 40 |
| 1000 6 12.1 73 |
| 2000 6 12.5 79 |
| 4000 6 13.5 93 |
| Saline -- 27 7.0 0 |
| 15 6 8.1 15 |
| 5-FU 30 6 8.8 25 |
| (Saline) 60 6 9.7 38 |
| FT-207 50 6 7.0 0 |
| (Saline) 200 6 7.1 1 |
| ______________________________________ |
From Table 5, it cannot be confirmed that FT-207 is effective in a dose of about 1/4 LD50. On the contrary, it can be confirmed that Compound A is effective even in a dose of about 1/8 LD50.
Additionally, in comparison of the dose of the Compound A with that of 5-FU, wherein the dose shows the corresponding increase in life-span (ILS), the ratio of said dose to the LD50 in the Compound A is smaller than that of 5-FU. Therefore, the availability of the Compound A is higher than that of 5-FU.
(2) Duration of antitumor activity
Administration
To test group:
Compound A was intraperitoneally administered in CDF1 mice (female, 8-10 weeks old) as a solution of MCT, before the implantation as shown in Table 6.
Each of FT-207 and 5-FU was intraperitoneally administered as a saline solution, before the implantation as shown in Table 6.
To control groups:
MCT was administered as control for Compound A.
Saline solution was administered as controls for FT-207 and 5-FU.
Implantation
105 cells of L-1210 leukemia were intraperitoneally implanted in the mice.
Observation
Survival days after the implantation were counted. The results were shown in Table 6.
| Table 6 |
| ______________________________________ |
| Administration |
| time of drugs |
| (number of days |
| Number Mean |
| Drugs before tumor of servival |
| administered |
| implantation) |
| animals days |
| ______________________________________ |
| No admini- -- 7 9.1 |
| stration |
| 0 4 9.0 |
| 1 8 10.3 |
| MCT 2 7 10.1 |
| (control) 3 7 10.1 |
| 4 7 9.9 |
| 6 5 9.0 |
| 0 8 11.6 |
| Compound A 1 6 13.0 |
| (Dose : 1000 |
| 2 8 16.4 |
| mg/Kg) 3 8 11.8 |
| 4 7 11.2 |
| 6 4 13.5 |
| 1 5 8.8 |
| Saline 2 5 9.0 |
| 4 5 9.0 |
| FT-207 (Saline) |
| 1 5 8.8 |
| (Dose : 200 2 5 9.0 |
| mg/Kg) 4 5 9.0 |
| 5-FU (Saline) |
| 1 5 9.0 |
| (Dose 50 mg/Kg) |
| 2 5 9.0 |
| 4 5 8.8 |
| ______________________________________ |
In Table 6, it is shown that Compound A exhibits survival effects by administration either on the same day of the implantation of the tumor cells, or on 1-6 days prior to the implantation, and that Compound A shows antitumor effects for 6 days.
As described above, the derivatives of this invention have very lower toxicity and a broader range between toxic dose and effective dose than those of 5-FU and FT-207. Duration of the derivatives of this invention is more effective than with 5-FU and FT-207. In these points, the derivatives of this invention are excellent antitumor agents.
Dose of the derivatives of this invention as antitumor agents amount to about 1-200 mg/Kg per day, preferably 5-100 mg/Kg for adult.
The derivatives of this invention may be administered either orally or parenterally. As the administration form, powder, granule, tablet, capsule, liquid for injection, suppository and ointment can be available.
These formulations can be prepared by using a conventional excipient by means of a conventional process.
The following examples are illustrative of this invention, and are not to be construed as a limitation of the invention, parts and percentages being by weight unless otherwise specified.
PAC Synthesis of N1 -d,l-α-tocopheryl carbonyl-5-fluorouracilA suspension was prepared by adding 10.3 g (0.13 mols) of 55% oily sodium hydride to 100 ml of dimethyl formamide. The suspension was cooled to below 5°C 150 ml of dimethyl formamide solution containing 16.9 g (0.13 mols) of 5-fluorouracil were added slowly dropwise to the suspension while stirring for 30 minutes, and the mixed solution was further kept for one hour at the same condition. To the solution, 100 ml of dimethyl formamide solution containing 64.1 g (0.13 mols) of d,l-α-tocopheryl chloroformate were added slowly dropwise for 30 minutes. The solution was heated to 40°C and stirred for additional one hour. After the stirring, the reaction solution was allowed to cool to a room temperature, and subjected to the filtration. The filtrate was concentrated under a reduced pressure. The resulting residue in the amount of 76 g was extracted twice with 300 ml of benzene, respectively. The benzene extract was concentrated under a reduced pressure. The resulting residue in the amount of 71 g was recrystallized from ethanol to obtain the object material in a white crystalline powder having a melting point of 119°-120°C
Yield: 64.7 g (85%)
Elementary analysis of the compound having the presumable formula C34 H51 FN2 O5 gives the following data.
| ______________________________________ |
| C H N |
| ______________________________________ |
| Calculated (%) |
| 69.59 8.76 4.77 |
| Found (%) 69.44 8.70 4.79 |
| ______________________________________ |
Infrared absorption spectrum: (KBr method)
Three absorption bands due to carbonyl group are observed in a range of 1700-1770 cm-1.
Nuclear magnetic resonance spectrum: (CDCl3)
δ 8.22 (d:1, J5-6 = 8.0Hz, H6)
2.60 (t:2 J = 7Hz)
2.09-2.04 (s:9 Phenylmethyl group)
1.80 (t:2, J = 7Hz)
1.60-1.18 (m:18)
0.9-0.8 (d:15)
Mass spectrum: M+ = 586
PAC Synthesis of N1 -(2,2,5,7,8-pentamethyl chromanyl-6-carbonyl)-5-fluorouracil2.47 g (0.019 mols) of 5-fluorouracil and 5.13 g (0.019 mols) of 2,2,5,7,8-pentamethylchromanyl-6-chloroformate were subjected to the reaction and the subsequent treatment according to the procedure of Example 1. The object material was thus obtained in a form of a white crystalline powder having a melting point of 208°-210°C
Yield: 4.9 g (68.5%)
Elementary analysis of the compound having the presumable formula C19 H21 FN2 O5 gives the following data.
| ______________________________________ |
| C H N |
| ______________________________________ |
| Calculated (%) |
| 60.63 5.60 7.40 |
| Found (%) 60.75 5.58 7.41 |
| ______________________________________ |
Infrared absorption spectrum: (KBr method)
Three absorption bands due to the carbonyl group were observed in a range of 1700-1770 cm-1.
Nuclear magnetic resonance spectrum: (deutero pyridine)
δ 8.24 (d = 1 J5-6 = 8.0Hz, H6)
2.62 (t = 2 J = 7Hz)
2.08-2.04 (s = 9 phenylmethyl group)
1.82 (t = 2, J = 7Hz)
1.32 (s = 6 methyl group)
The compounds according to this invention are shown as examples in the following table.
| __________________________________________________________________________ |
| ##STR4## |
| Molecular |
| Elementary analysis (%) |
| formula Calculated |
| Example Melting Found |
| No. R1 |
| R2 |
| R3 |
| R4 point (° C) |
| C H N F Remarks |
| __________________________________________________________________________ |
| 3 CH3 |
| CH3 |
| CH3 |
| ##STR5## |
| ##STR6## |
| ##STR7## |
| ##STR8## |
| ##STR9## |
| ##STR10## |
| d,l - form |
| 4 CH3 |
| CH3 |
| CH3 |
| ##STR11## |
| ##STR12## |
| ##STR13## |
| ##STR14## |
| ##STR15## |
| ##STR16## |
| d,l - form |
| 5 H CH3 |
| CH3 |
| ##STR17## |
| ##STR18## |
| ##STR19## |
| ##STR20## |
| ##STR21## |
| ##STR22## |
| d - form |
| 6 H H CH3 |
| ##STR23## |
| ##STR24## |
| ##STR25## |
| ##STR26## |
| ##STR27## |
| ##STR28## |
| d - form |
| 7 CH3 |
| CH3 |
| CH3 |
| ##STR29## |
| ##STR30## |
| ##STR31## |
| ##STR32## |
| ##STR33## |
| ##STR34## |
| d - form |
| 8 CH3 |
| CH3 |
| CH3 |
| ##STR35## |
| ##STR36## |
| ##STR37## |
| ##STR38## |
| ##STR39## |
| ##STR40## |
| d,l - |
| __________________________________________________________________________ |
| form |
| ______________________________________ |
| N1 -d,1-α-tocopheryl carbonyl-5-fluorouracil |
| 80 g |
| Micro-crystallized cellulose |
| 40 g |
| Corn starch 15 g |
| Lactose 12 g |
| Polyvinyl pyrolidone 3 g |
| Total 150 g |
| ______________________________________ |
In accordance with the above formulation, N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch and lactose were mixed altogether. Aqueous polyvinyl pyrolidone solution was added as a binder to this mixture, and the whole was granulated by a conventional process. These granules were filled in hard gelatinous capsules, to form the capsules.
PAC Tablet| ______________________________________ |
| N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil |
| 100 g |
| Micro-crystallized cellulose |
| 40 g |
| Corn starch 14 g |
| Lactose 20 g |
| Calcium carboxymethyl cellulose |
| 10 g |
| Polyvinyl pyrolidone 6 g |
| Talc 10 g |
| Total 200 g |
| ______________________________________ |
According to the above formulation, N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch, lactose and calcium carboxymethyl cellulose were mixed altogether. Aqueous polyvinyl pyrolidone solution was added as a binder to said mixture, and the whole was granulated by a conventional process. The granules were admixed with the talc, to form tablets of 200 mg per tablet.
PAC Liquid for injection| ______________________________________ |
| N1 -d-γ-tocopheryl carbonyl-5-fluorouracil |
| 10 g |
| Nikko HCO-60 (Trade Mark, Nikko Chemical |
| 40 g |
| Company, Japan) |
| Propylene glycol 80 g |
| Sorbitol 20 g |
| Distilled water sufficient to make up total |
| 1 liter |
| ______________________________________ |
According to the above formulation, a liquid for injection was prepared by a conventional method.
PAC SuppositoryForty grams of N1 -d,l-α-tocopheryl carbonyl-5-fluorouracil were dissolved in one liter of O. D. O. (medium chain triglyceride produced and sold by Nisshin Oil Co., Ltd., Japan). This solution was put in a film of soft capsule of gelatine to obtain a suppository.
Arai, Haruyoshi, Kijima, Shizumasa, Hamamura, Kimio, Shionoya, Hiroshi, Koyanagi, Nozomu
| Patent | Priority | Assignee | Title |
| 11034667, | Jan 09 2017 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| 11584733, | Jan 09 2017 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| 4558127, | Mar 07 1984 | 5-Fluorouracil nitroxyl derivatives possessing antitumor activity |
| Patent | Priority | Assignee | Title |
| 3971784, | Nov 28 1973 | Mitsui Pharmaceuticals, Incorporated | 5-Fluorouracil derivatives |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Dec 14 1977 | Eisai Co., Ltd. | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Dec 19 1981 | 4 years fee payment window open |
| Jun 19 1982 | 6 months grace period start (w surcharge) |
| Dec 19 1982 | patent expiry (for year 4) |
| Dec 19 1984 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 19 1985 | 8 years fee payment window open |
| Jun 19 1986 | 6 months grace period start (w surcharge) |
| Dec 19 1986 | patent expiry (for year 8) |
| Dec 19 1988 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 19 1989 | 12 years fee payment window open |
| Jun 19 1990 | 6 months grace period start (w surcharge) |
| Dec 19 1990 | patent expiry (for year 12) |
| Dec 19 1992 | 2 years to revive unintentionally abandoned end. (for year 12) |